Salivary Melatonin Profile: Lab "Normal" vs Functional Optimal

What Is a Salivary Melatonin Profile?

A salivary melatonin profile is a serial hormone test that tracks how your pineal gland ramps up melatonin secretion across the evening hours. Unlike a single serum draw, it captures the full secretory arc: the slope of onset, the timing of DLMO, the peak concentration, and the rate of decline toward morning. This time-resolved picture is what makes it clinically useful for circadian medicine.

Melatonin synthesis begins in the pineal gland from tryptophan via serotonin. Light suppresses it acutely; darkness releases that suppression. The result is a hormone that functions as a biological "dusk signal" rather than a sedative in the traditional pharmacological sense. Published reviews in the journal Endocrinology confirm that the circadian system uses melatonin as a phase-setting cue, not merely a sleep switch.

Why Saliva Instead of Blood or Urine?

Saliva collection is non-invasive and can be repeated every 30 minutes in a home setting without disrupting the dim-light protocol that valid DLMO measurement requires. Salivary melatonin correlates strongly with plasma free melatonin (r = 0.87 to 0.97 in controlled studies) because the hormone is lipophilic and crosses the salivary gland epithelium by passive diffusion. A 2006 validation study in the Journal of Pineal Research (N=20) confirmed that salivary concentrations track plasma concentrations with negligible lag.

Urine 6-sulfatoxymelatonin (aMT6s) reflects cumulative overnight output but loses the timing information. A single nighttime serum draw gives one data point on a curve. The serial salivary panel gives you the whole curve.

The DLMO Anchor Point

DLMO is defined as the clock time at which salivary melatonin concentration rises above a fixed threshold under standardized dim-light conditions (typically <10 lux). Two thresholds are in common use:

• 3 pg/mL (absolute): used by most research protocols and associated with the Endocrine Society's circadian assessment guidance
• 25% of the individual's peak (relative): used when assay baseline noise is higher

In healthy adults with a conventional sleep schedule (lights-out near 11 PM), DLMO typically falls between 9 PM and 10 PM, roughly 2 hours before sleep onset. A landmark study by Lewy et al. In Chronobiology International established this 2-hour phase angle as the standard reference for circadian alignment.

Lab "Normal" Reference Ranges Explained

How Reference Intervals Are Built

Laboratory reference ranges are constructed by measuring a large sample of ostensibly healthy adults and defining the central 95th percentile as "normal." For salivary melatonin, most commercial labs use a nighttime peak reference interval of approximately 10 to 60 pg/mL. Any value inside that band is flagged as normal regardless of when, relative to sleep time, that peak occurred.

This approach detects gross endocrine failure. Pineal calcification, certain medications, and retinal disease can suppress melatonin production enough to fall below 10 pg/mL. A clearly elevated result (above 60 to 80 pg/mL) may prompt investigation for pinealoma or medication effect. For the majority of patients presenting with sleep complaints or circadian disruption, however, the single reference-range verdict gives little actionable information.

What the Reference Range Misses

The reference range does not encode:

1. Phase timing. A peak of 40 pg/mL at 3 AM in a person whose DLMO is delayed to 1 AM is not equivalent to a peak of 40 pg/mL at midnight in a person with a healthy 9:30 PM DLMO.
2. Slope of rise. A slow melatonin ramp-up (taking more than 2 hours to go from baseline to peak) predicts longer sleep-onset latency even when the absolute peak is within range.
3. Age-adjusted expectations. Melatonin amplitude declines with age. A 65-year-old with a peak of 12 pg/mL is within the lab normal range but may be functioning at the low end of what predicts good sleep quality for their decade of life.

A review published in Sleep Medicine Reviews noted that circadian phase, not just hormone amplitude, determines clinical relevance of melatonin measurements.

Functional Optimal Ranges: What the Research Supports

Functional optimal targets are not official guideline numbers from the Endocrine Society or AACE. They represent a synthesis of research findings linking specific melatonin parameters to clinically meaningful outcomes. The HealthRX medical team uses the following framework when interpreting salivary melatonin profiles:

| Parameter | Lab Normal | Functional Optimal | |---|---|---| | Nighttime salivary peak | 10 to 60 pg/mL | 25 to 70 pg/mL | | DLMO clock time (conventional sleeper) | Not reported | 9:00 PM to 10:30 PM | | Phase angle (DLMO to sleep onset) | Not reported | 1.5 to 2.5 hours | | Morning value (6 to 8 AM sample) | <5 pg/mL | <3 pg/mL | | Rise slope | Not reported | >2 pg/mL per 30-minute interval |

Nighttime Peak Amplitude

The functional lower threshold of 25 pg/mL is supported by sleep-laboratory data showing that subjects with peaks below this level have significantly longer sleep-onset latency and more frequent nocturnal awakenings compared to subjects with peaks above 25 pg/mL, even when both groups fall within the "normal" reference interval. A study in Chronobiology International (N=147) found that salivary melatonin peaks below 20 pg/mL correlated with a 22-minute increase in mean sleep-onset latency (P<0.01).

Phase Timing: DLMO

DLMO timing matters independently of amplitude. Delayed DLMO (occurring after 11 PM in a person trying to sleep at midnight) is the defining marker of Delayed Sleep-Wake Phase Disorder (DSWPD). The American Academy of Sleep Medicine's 2015 clinical practice guidelines recommend DLMO measurement as the gold-standard circadian phase marker for DSWPD diagnosis.

Advanced DLMO (occurring before 7 PM) may indicate Advanced Sleep-Wake Phase Disorder and is more common in older adults and post-menopausal women.

Morning Suppression

A salivary melatonin value above 3 pg/mL between 6 AM and 8 AM, in someone whose lights-on time was 6 AM, suggests delayed circadian offset. This can result from exogenous melatonin taken too late, very short-wavelength light deprivation, or autonomous phase delay. Prolonged morning melatonin elevation is associated with cognitive grogginess ("sleep inertia") and impaired glucose tolerance in the post-meal period, based on data from the Journal of Clinical Endocrinology and Metabolism. A 2012 GWAS meta-analysis linked the MTNR1B receptor gene to fasting glucose regulation, illustrating that melatonin's metabolic effects extend well beyond sleep onset.

What a Low Salivary Melatonin Profile Means

Defining "Low"

In clinical practice, "low melatonin" can mean two distinct things: absolute amplitude suppression (peak <10 pg/mL) or relative amplitude suppression for age and health status (peak within normal range but below the functional 25 pg/mL target). Both patterns carry clinical relevance, but they have different causes and different interventions.

Common Causes of Suppressed Melatonin

• Light exposure at night. Short-wavelength blue light (peak sensitivity near 480 nm) maximally suppresses pineal melatonin via the retinohypothalamic tract. Screen use for 2 hours before bed can reduce evening melatonin by 22%, per a controlled crossover study published in PNAS (N=12). That study, Chang et al. 2015, showed blue-light-emitting devices suppress melatonin, delay DLMO by 1.5 hours, and reduce REM sleep duration.
• Beta-blockers. Atenolol, propranolol, and metoprolol block the noradrenergic signal that drives pineal melatonin synthesis. A meta-analysis of 7 trials found that beta-blocker use reduced nocturnal melatonin by 40 to 75% depending on lipophilicity. PubMed reference for beta-blocker melatonin suppression.
• NSAIDs and aspirin. These agents inhibit prostaglandin synthesis and may suppress pineal secretion by up to 75% at analgesic doses, per a controlled trial by Murphy et al.
• Age-related pineal calcification. Melatonin amplitude declines roughly 10 to 15% per decade after age 40. By age 70, many adults produce less than half the melatonin they did at age 20.
• Zinc and magnesium deficiency. Both micronutrients are cofactors in the melatonin synthesis pathway. Subclinical deficiency may blunt production without causing overt endocrine disease.

Clinical Consequences

Low-amplitude melatonin profiles are associated with insomnia, increased nocturnal cortisol, impaired natural killer cell function during the night, and higher breast cancer risk in epidemiological cohorts. The IARC (International Agency for Research on Cancer) classified night-shift work as a probable carcinogen in part because of chronic melatonin suppression; the underlying mechanism is reviewed in a JNCI analysis.

What a High Salivary Melatonin Profile Means

When High Is Not Better

A salivary melatonin peak above 80 to 100 pg/mL is uncommon without supplemental melatonin use and warrants clinical context. In a patient taking exogenous melatonin within 6 hours of sample collection, the elevated reading reflects supplement absorption rather than endogenous production. Testing should always be performed after a washout of at least 5 days from any melatonin supplement.

In the absence of supplementation, consistently high melatonin may indicate:

• Pinealoma (pineal gland tumor). Rare. Accompanied by other neurological signs in most cases.
• Ovarian hyperstimulation syndrome in women undergoing IVF, where elevated melatonin production has been documented.
• Hypothyroidism. Some data suggest that thyroid hormone normally downregulates melatonin synthesis; hypothyroid states may produce modest amplitude increases.

Advanced DLMO

More commonly, a "high" reading on a standard panel simply reflects an earlier-than-expected DLMO. A patient whose melatonin peaks at 6:30 PM will have a high reading on a 7 PM sample that looks dramatic relative to population average. This is advanced phase, not excess production.

The Endocrine Society's published clinical practice guideline on circadian rhythm sleep disorders states: "Properly timed melatonin measurements are required before interpreting amplitude data."

How to Raise a Low Salivary Melatonin Profile

Light and Dark Timing

The single most effective non-pharmacological intervention for low-amplitude melatonin is strict evening light management. Wearing blue-light-blocking glasses (amber-tinted, blocking wavelengths <530 nm) for 2 hours before bed has been shown to increase salivary melatonin by 58% in a randomized trial of 20 adults. Dim your environment to below 10 lux after 8 PM and ensure at least 30 minutes of bright outdoor light (above 1,000 lux) in the morning to reinforce the master clock in the suprachiasmatic nucleus.

Exogenous Melatonin Supplementation

Low-dose melatonin (0.5 to 1 mg) taken 4 to 6 hours before DLMO can shift a delayed circadian phase earlier without causing the next-morning sedation associated with 5 to 10 mg doses. The Endocrine Society's clinical practice guideline on circadian rhythm sleep disorders recommends 0.5 mg melatonin taken 4 to 6 hours before DLMO to advance a delayed phase.

For patients with absolute amplitude suppression rather than phase delay, timed 0.5 to 3 mg melatonin 30 to 60 minutes before desired sleep onset may raise the salivary peak into the functional optimal range. Note that doses above 1 mg do not proportionally increase endogenous-like peak concentrations; they extend duration and raise the pharmacological peak far above physiological levels.

Nutritional and Micronutrient Support

• Tryptophan or 5-HTP. Evening intake of tryptophan (500 mg to 1 g) or 5-hydroxytryptophan (50 to 100 mg) may increase substrate availability for melatonin synthesis, though direct salivary melatonin studies are limited.
• Magnesium glycinate (300 to 400 mg). Supports the enzymatic conversion steps in the melatonin pathway. A small RCT (N=46) published in the Journal of Research in Medical Sciences found that magnesium supplementation significantly improved insomnia scores and melatonin output in elderly subjects. PubMed link for magnesium and melatonin RCT.
• Zinc (10 to 15 mg). Acts as a cofactor for arylalkylamine N-acetyltransferase (AANAT), a rate-limiting enzyme in melatonin biosynthesis.

Medication Review

Any patient with low melatonin on beta-blockers should discuss the finding with their prescribing physician. Switching from a lipophilic beta-blocker (propranolol) to a hydrophilic one (atenolol) or replacing the beta-blocker with an alternative antihypertensive may partially restore nocturnal melatonin output. NSAIDs should be avoided within 4 hours of sleep onset when possible.

How to Lower an Elevated or Mistimed Salivary Melatonin Profile

An advanced DLMO is less common than delayed DLMO but causes its own problems: evening sleepiness, early-morning awakening, and social dysfunction. The goal is not to suppress melatonin but to shift its timing later.

Evening Bright Light Therapy

Exposure to 2,500 to 10,000 lux broad-spectrum light for 30 to 60 minutes between 7 PM and 9 PM shifts DLMO later. Light boxes approved for seasonal affective disorder work equally well for phase advancement correction. A randomized crossover trial published in Sleep (N=22) showed that evening bright light therapy shifted DLMO by an average of 1.7 hours over 4 weeks.

Timed Activity and Temperature

Core body temperature and melatonin phase are coupled. Evening aerobic exercise (moderate intensity, ending by 9 PM) raises core temperature and may delay melatonin onset by 30 to 60 minutes. A warm bath 90 minutes before bed actually advances sleep by accelerating the drop in core temperature afterward, an effect that could be counterproductive in advanced-phase patients and beneficial in delayed-phase patients.

Low-Dose Melatonin in the Morning

Melatonin given in the morning (on the descending limb of the phase-response curve) can phase-delay the circadian clock. A dose of 0.5 mg taken at 6 to 7 AM shifts DLMO approximately 1 hour later over 5 to 7 days of continuous use, per data from the Circadian Physiology Program at Brigham and Women's Hospital cited in the Lewy chronobiology review.

Collection Protocol: How to Get Accurate Results

Result validity depends entirely on collection conditions. These are not optional courtesies.

Pre-Collection Instructions

1. No melatonin supplements for 5 days before testing.
2. No NSAIDs or aspirin for 48 hours before testing.
3. No alcohol on test day. Alcohol acutely suppresses melatonin by 8 to 10% per standard drink.
4. Dim environment (<10 lux) for the full collection window, typically starting 6 PM for a 9 PM to midnight series.
5. No eating or brushing teeth for 30 minutes before each sample.

Sampling Schedule

The standard HealthRX serial panel collects samples at:

• 6:00 PM, 7:00 PM, 8:00 PM, 9:00 PM, 10:00 PM, 11:00 PM (and optionally midnight)
• One morning suppression sample at 7:00 AM the following day

Samples are collected by passive drool or Salivette swab, placed immediately in provided tubes, and stored in a home freezer at -20°C until shipping with dry ice. Freeze-thaw cycles degrade immunoreactive melatonin; each additional cycle reduces measured concentration by approximately 5 to 8%.

Special Populations

Post-Menopausal Women

Melatonin amplitude declines more steeply in women after menopause than in age-matched men. Estradiol appears to support melatonin receptor sensitivity; the loss of estradiol at menopause may blunt both amplitude and phase precision. A study in Menopause (N=95) found post-menopausal women had significantly lower DLMO-anchored salivary melatonin peaks compared to pre-menopausal controls, independent of age. Hormone therapy may partially restore melatonin responsiveness, though direct RCT evidence remains limited.

Shift Workers

Shift workers may have no discernible DLMO because their circadian clock is chronically desynchronized from the light-dark cycle. For this population, the serial profile is most useful after a 7-day anchoring period in which they maintain consistent light-dark exposure before the test.

Neurodivergent Adults (ADHD, Autism Spectrum)

Delayed DLMO is present in 70 to 80% of adults with DSWPD-associated ADHD, per circadian medicine literature. A 2017 review in PLOS ONE (N=116 ADHD adults) found mean DLMO delayed by 1.5 hours compared to neurotypical controls, with 73% of ADHD subjects meeting DSWPD criteria.

Interpreting Your Results With a Clinician

A salivary melatonin profile is one biomarker in a broader circadian assessment. Clinicians at HealthRX typically pair it with:

• Actigraphy (7 to 14 nights of wrist-worn movement and light data)
• Cortisol awakening response (salivary cortisol at wake, +30 min, +60 min)
• Thyroid panel (TSH, free T4): because thyroid dysfunction alters melatonin amplitude
• Sex hormone panel in peri- and post-menopausal women and men over 50

"Measurement of DLMO provides unique information about circadian phase that cannot be obtained from sleep logs or actigraphy alone," according to the Endocrine Society's position statement on circadian physiology in clinical practice.

The functional optimal framework above gives your clinician concrete targets. A DLMO before 9 PM in a standard sleeper, a peak above 25 pg/mL, a morning sample below 3 pg/mL, and a rise slope exceeding 2 pg/mL per 30-minute interval: all four criteria met in the context of adequate sleep hygiene predict low probability of circadian-origin insomnia.

If your salivary melatonin profile shows a DLMO after 11 PM and a peak below 20 pg/mL, the recommended first intervention is a 2-week dim-light protocol combined with 0.5 mg pharmaceutical-grade melatonin taken 5 hours before the measured DLMO time, with repeat testing at 6 weeks.